SAN
DIEGO, Jan. 2, 2024 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) will present at the
42nd Annual J.P. Morgan Healthcare Conference at
9:45 a.m. Pacific Time on Tuesday
January 9, 2024 in San Francisco.
Kevin Gorman, Chief Executive
Officer, will present at the conference.
The live presentation will be webcast and may be accessed on the
Company's website under Investors at www.neurocrine.com. A replay
of the presentation will be available on the website approximately
one hour after the conclusion of the events and will be archived
for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is
a leading neuroscience-focused, biopharmaceutical company with a
simple purpose: to relieve suffering for people with great needs,
but few options. We are dedicated to discovering and developing
life-changing treatments for patients with under-addressed
neurological, neuroendocrine, and neuropsychiatric disorders. The
company's diverse portfolio includes FDA-approved treatments for
tardive dyskinesia, chorea associated with Huntington's disease,
endometriosis* and uterine fibroids*, as well as a robust pipeline
including multiple compounds in mid- to late-phase clinical
development across our core therapeutic areas. For three decades,
we have applied our unique insight into neuroscience and the
interconnections between brain and body systems to treat complex
conditions. We relentlessly pursue medicines to ease the burden of
debilitating diseases and disorders, because you deserve brave
science. For more information, visit neurocrine.com, and
follow the company on LinkedIn, X (Formerly Twitter) and Facebook.
(*in collaboration with AbbVie)
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-42nd-annual-jp-morgan-healthcare-conference-302024759.html
SOURCE Neurocrine Biosciences, Inc.